CHIMERIX
Chimerix is developing novel antiviral therapeutics with the potential to transform patient care in multiple settings, including transplant, oncology, acute care and global health. The company's lead candidate, CMX001, is being developed as a potential broad spectrum antiviral agent for the treatment of life-threatening double-stranded DNA (dsDNA) viral diseases. Over 350 people have received CMX001 to date, with a growing body of evidence supporting the drug's antiviral activity in humans. ... Clinical studies of CMX001 include an ongoing Phase 2 study of the prevention/control of cytomegalovirus (CMV) in hematopoietic stem cell transplant patients (CMX001-201), a Phase 2 study being initiated for the treatment of adenovirus (AdV) infection in pediatric and adult hematopoietic stem cell transplant patients (CMX001-202), and an Open-Label Study (CMX001-350) for the treatment of any of 12 different dsDNA viral infections, including AdV, herpes viruses such as CMV, herpes simplex virus and Epstein Barr virus, polyoma viruses such as BK virus and JC virus, and pox viruses. The Open-Label Study builds on Chimerixรขโฌโขs extensive experience working with clinicians at over 55 leading institutions in the United States, Canada, Europe and Israel who have sought CMX001 for the treatment of more than 150 immunocompromised patients under Emergency INDs. CMX001 has been well tolerated in all studies. CMX001 is also being developed as a medical countermeasure in the event of a smallpox release. Chimerix has received significant federal funding for the development of CMX001 as a medical countermeasure against smallpox from the National Institute of Allergy and Infectious Diseases. Chimerix's second clinical-stage antiviral compound, CMX157, a potent nucleoside analogue with in vitro activity against HIV and hepatitis B, has the potential to directly address several limitations of current HIV therapies. Chimerix is developing CMX157 for the treatment of HIV infection including those caused by multi-drug resistant viruses. A Phase 1 clinical study has been completed demonstrating that the compound is well tolerated and that the active antiviral, TFV-PP, was measurable in peripheral blood mononuclear cells (PBMCs) after a single dose and remained detectable for six days, indicating that it may be suitable for once-weekly dosing. Led by a world-class antiviral drug development team, Chimerix is also leveraging the company's extensive chemical library to pursue new treatments for hepatitis C virus, flu, malaria and other global public health needs.
CHIMERIX
Industry:
Biotechnology Health Care Pharmaceutical
Founded:
2002-01-01
Address:
Durham, North Carolina, United States
Country:
United States
Website Url:
http://www.chimerix.com
Total Employee:
51+
Status:
Active
Contact:
9193136782
Email Addresses:
[email protected]
Total Funding:
441.25 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Apple Mobile Web Clips Icon WordPress Font Awesome Domain Not Resolving Wordpress Plugins Sitelinks Search Box
Similar Organizations
Axcella
Axcella is a biotechnology company providing therapeutics development solutions.
AZTherapies
AZTherapies is a clinical stage biotech company developing breakthrough treatments for neuroinflammation-related diseases.
EpiVax
EpiVax is an immunology company developing comprehensive analytical capabilities in the field of computational immunology.
Immutep
Immutep is a biopharmaceutical company developing immunotherapeutics in oncology.
IVERIC bio
IVERIC bio is a biopharmaceutical company developing novel therapies for age-related macular degeneration.
Soligenix
Soligenix is a biopharmaceutical company that develops biodefense vaccines and therapeutics to treat rare diseases.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Acquisitions List
Date | Company | Article | Price |
---|---|---|---|
2021-01-08 | Oncoceutics | Oncoceutics acquired by Chimerix | 78 M USD |
Investors List
Alta Partners
Alta Partners investment in Series F - Chimerix
Pappas Ventures
Pappas Ventures investment in Series F - Chimerix
New Leaf Venture Partners
New Leaf Venture Partners investment in Series F - Chimerix
Sanderling Ventures
Sanderling Ventures investment in Series F - Chimerix
Frazier Healthcare Partners
Frazier Healthcare Partners investment in Series F - Chimerix
Canaan Partners
Canaan Partners investment in Series F - Chimerix
Asset Management Ventures (AMV)
Asset Management Ventures (AMV) investment in Series F - Chimerix
Morningside Group
Morningside Group investment in Series F - Chimerix
Asset Management Ventures (AMV)
Asset Management Ventures (AMV) investment in Series E - Chimerix
Alta Partners
Alta Partners investment in Series E - Chimerix
Key Employee Changes
Date | New article |
---|---|
2022-08-08 | Chimerix Appoints Christopher L. Jordan as Vice President, Regulatory AffairsBrings 30 Years of Experience as a Former Endocyte and Novartis Regulatory Executive |
Official Site Inspections
http://www.chimerix.com Semrush global rank: 95.54 K Semrush visits lastest month: 1.05 M
- Host name: 172.67.43.91
- IP address: 172.67.43.91
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago